GS
ATNM icon

Gagnon Securities’s Actinium Pharmaceuticals ATNM Stock Holding History

Gagnon Securities’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200K Sell
201,300
-507
-0.3% -$603 0.05% 82
2025
Q4 		$274K Sell
201,807
-24,450
-11% -$35.7K 0.06% 77
2025
Q3 		$362K Sell
226,257
-365
-0.2% -$595 0.07% 71
2025
Q2 		$317K Hold
226,622
– – 0.06% 70
2025
Q1 		$365K Buy
+226,622
New +$288K 0.08% 70

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Gagnon Securities's ATNM Position: Q1 2026 in Review

Gagnon Securities reduced its Actinium Pharmaceuticals (ATNM) stake by 0.25% in Q1 2026, selling an estimated $603 and leaving 201,300 shares worth $200K. The position accounts for 0.05% of the portfolio, ranked #82.

Gagnon Securities first reported a position in ATNM in Q1 2025 and has held it in 5 quarters since. The position peaked at $365K in Q1 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Gagnon Securities held 201,300 shares of Actinium Pharmaceuticals worth $200K as of Q1 2026.
  • Gagnon Securities sold 507 Actinium Pharmaceuticals shares in Q1 2026, an estimated $603.
  • Actinium Pharmaceuticals made up 0.05% of Gagnon Securities's portfolio in Q1 2026, its #82 holding.
  • Gagnon Securities first reported a position in Actinium Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Gagnon Securities's Actinium Pharmaceuticals position peaked at $365K in Q1 2025.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Gagnon Securities's 13F filing for Q1 2026, filed 22 Apr 2026.